NASDAQ:DARA

(DARA) (DARA) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$0.32
$0.33
52-Week Range
N/A
Volume
13,850 shs
Average Volume
118,843 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
DARA stock logo

About (DARA) Stock (NASDAQ:DARA)

DARA BioSciences Inc is specialty pharmaceutical company based in the United States. The Company’s primary focus is on the commercialization of oncology treatment and oncology supportive care pharmaceutical products, including Soltamox, an oral solution of tamoxifen citrate; cancer support therapeutics, including Gelclair, indicated for the treatment of oral mucositis and Bionect, for the management of irritation of the skin as well as first and second degree burns, and Three Mission Pharmacal products, including Ferralet 90 (for anemia), Binosto (alendronate sodium effervescent tablet indicated for the treatment of osteoporosis) and Aquoral (for cancer related dry mouth). The Company has a clinical development asset, KRN5500, which is a Phase II product candidate targeted for treating cancer patients with painful treatment-refractory chronic chemotherapy induced peripheral neuropathy. The Company is a subsidiary of Midatech Pharma Plc.

DARA Stock News Headlines

“The Biggest Bubble of All Time” – Here’s What to Do.
Despite AI's incredible run-up in 2023, we're getting some conflicting messages. Analysts at JP Morgan warn that an "AI-driven bubble" could drag the entire stock market down. Folks at Morgan Stanley say AI hysteria is creating conditions like the dot-com collapse. Even AI leaders (the people who benefit the most!) are getting worried.
“The Biggest Bubble of All Time” – Here’s What to Do.
Despite AI's incredible run-up in 2023, we're getting some conflicting messages. Analysts at JP Morgan warn that an "AI-driven bubble" could drag the entire stock market down. Folks at Morgan Stanley say AI hysteria is creating conditions like the dot-com collapse. Even AI leaders (the people who benefit the most!) are getting worried.
Supporting survivors and raising awareness
PEOPLE's 24 Hour Food Tour: Boston
See More Headlines
Receive DARA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (DARA) and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2015
Today
4/25/2024

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:DARA
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

DARA Stock Analysis - Frequently Asked Questions

How were (DARA)'s earnings last quarter?

(DARA) (NASDAQ:DARA) issued its quarterly earnings data on Monday, November, 2nd. The specialty pharmaceutical company reported ($0.14) EPS for the quarter, hitting analysts' consensus estimates of ($0.14). The specialty pharmaceutical company earned $1.18 million during the quarter, compared to analyst estimates of $0.83 million.

What other stocks do shareholders of (DARA) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other (DARA) investors own include Castleton Technology (CTP), Richland Resources Ltd (RLD.L) (RLD), Thor Energy (THR), Global Invacom Group (GINV), Legendary Investments (LEG), iPass (IPAS), Aeterna Zentaris (AEZS), Clontarf Energy (CLON) and MoSys (MOSY).

This page (NASDAQ:DARA) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners